TELASSMO 40mg / 5mg tablets medication leaflet

C09DB04 telmisartan + amlodipine • Cardiovascular system | Angiotensin II receptor blockers (ARBs), combinations | Angiotensin ii receptor blockers (arbs) and calcium channel blockers

This combination of telmisartan and amlodipine is used for the treatment of hypertension in patients requiring combination therapy to control blood pressure. Telmisartan is an angiotensin II receptor antagonist, while amlodipine is a calcium channel blocker that relaxes blood vessels.

The medication is taken orally, usually once daily, as directed by a doctor. It is important for patients to follow the prescribed dosage and not discontinue treatment without consulting their doctor.

Patients should be aware of potential side effects, such as dizziness, edema, or headaches. It is important to inform the doctor of any unusual symptoms.

Common side effects include dizziness, edema, headaches, and fatigue. In rare cases, severe reactions such as kidney failure or allergic reactions may occur. Patients should be informed of these risks before starting treatment.

General data about TELASSMO 40mg / 5mg

Substance: telmisartan + amlodipine

Date of last drug list: 16-08-2017

Commercial code: W63585001

Concentration: 40mg / 5mg

Pharmaceutical form: tablets

Quantity: 14

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: KRKA, D.D., NOVO MESTO - SLOVENIA

Holder: KRKA, D.D., NOVO MESTO - SLOVENIA

Number: 14416/2022/01

Shelf life: 2 years

Concentrations available for telmisartan + amlodipine

40mg/10mg, 40mg/5mg, 80mg/10mg, 80mg/5mg